Aspira Women's Health Inc. entered into a Laboratory Services Agreement with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories, effective as of December 16, 2025.
On March 20, 2023, we entered into a licensing agreement with Harvard's Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz (the “Ovarian Cancer License Agreement”)
On March 20, 2023, we entered into a licensing agreement with Harvard's Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz (the “Ovarian Cancer License Agreement”)
On March 20, 2023, we entered into a licensing agreement with Harvard's Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Medical University of Lodz (the “Ovarian Cancer License Agreement”)
Aspira will provide certain reference laboratory testing services to Mayo, specifically the Ova1Plus (Ova1 and Overa) and OvaWatch tests, on a non-exclusive, as-requested basis for clinical purposes.
The Company also engages in channel distribution partnerships by which OvaSuite is distributed via laboratory partners such as BioReference Health, LLC, Associated Regional University Pathologists ("…
The Company also engages in channel distribution partnerships by which OvaSuite is distributed via laboratory partners such as BioReference Health, LLC, Associated Regional University Pathologists ("…
been unclear. ASU 2025-12 is effective for annual periods beginning after December 15, 2026, and interim periods within those annual periods, with early adoption permitted. Entities may adopt the gui…
Reciprocal relationship from DGX graph: Reciprocal relationship from AWHL graph: been unclear. ASU 2025-12 is effective for annual periods beginning after December 15, 2026, and interim periods withi…
Aspira Women's Health Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AWHL-DEBT
Debt stack $3.0M
90%
Market cache reports total debt of $3.0M.
AWHL-DEBT-8009
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
AWHL-DEBT-8008
Warrants outstanding: 366664
90%
xbrl warrant detail from xbrl 2025-12-31.
Aspira Women's Health Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aspira Women's Health Inc..
Aspira Women's Health Inc. Ownership
Holder
Name
Confidence
Evidence
AWHL-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 2 tracked holders.
Aspira Women's Health Inc. Extended Supply Chain Network
